SCHEMBL3587074

SCHEMBL3587074

NCc1ccc2c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)cccc2c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 12/20 0.83
PRKCA P17252 11/20 0.83
PRKCH P24723 7/20 0.62
PRKCE Q02156 7/20 0.62
PRKCQ Q04759 7/20 0.62
PRKCD Q05655 7/20 0.62
CAMK2D Q13557 4/20 0.59
PRKACA P17612 3/20 0.59
PRKACG P22612 3/20 0.59
PRKACB P22694 3/20 0.59
CDK4 P11802 3/20 0.59
CCND1 P24385 3/20 0.59
CDK2 P24941 3/20 0.59
ABL1 P00519 2/20 0.59
CCNE2 O96020 2/20 0.59
CCNE1 P24864 2/20 0.59
PRKD3 O94806 1/20 0.59
CCNB2 O95067 1/20 0.59
PRKCG P05129 1/20 0.59
CDK1 P06493 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547294 0.91 PRKCB (1.00) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL3582396 0.84 PRKCB (0.60) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL3540954 0.79 PRKCB (1.00) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL3543360 0.78 PRKCB (0.73) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL3584917 0.77 PRKCA (1.00) PRKCBPRKCAPRKCHPRKCEPRKCQ
Ro-316233 SCHEMBL29373011 0.77 PRKCB (1.00) PRKCBPRKCAPRKCHPRKCEPRKCQ
Ro-316233 SCHEMBL624896 0.77 PRKCB (1.00) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL9088865 0.74 PRKCB (0.74) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL6030821 0.73 PRKCB (0.68) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL6982683 0.72 PRKCB (0.67) PRKCBPRKCAPRKCHPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691861-B2 Indolymaleimide derivatives NOVARTIS AG (CH) 2010-04-06 US claimed
US-20080234494-A1 Indolylmaleimide Derivatives NOVARTIS AG (CH) 2008-09-25 US claimed
EP-1709030-B1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2008-04-02 EP claimed
JP-2007518730-A 2007-07-12 JP claimed
EP-1709030-A1 INDOLYLMALEIMIDE DERIVATIVES Novartis AG (CH) 2006-10-11 EP claimed
WO-2005068454-A1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2005-07-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234494-A1 Indolylmaleimide Derivatives IDH3A, INMT, IDH2 PRKCB 3670/4885PRKCA 3950/4885PRKCH 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.